Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)
Abstract Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patte...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-02-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01353-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850039631352954880 |
|---|---|
| author | Emily J. Goddard James M. Haughton James E. Lucas Sophie G. Barlow Timothy P. Fitzgerald Alexander M. Litvintchouk David Wu |
| author_facet | Emily J. Goddard James M. Haughton James E. Lucas Sophie G. Barlow Timothy P. Fitzgerald Alexander M. Litvintchouk David Wu |
| author_sort | Emily J. Goddard |
| collection | DOAJ |
| description | Abstract Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO. |
| format | Article |
| id | doaj-art-4565923da6814d738523cda238d9ceeb |
| institution | DOAJ |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-4565923da6814d738523cda238d9ceeb2025-08-20T02:56:16ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-02-0115366368010.1007/s13555-025-01353-xPatient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)Emily J. Goddard0James M. Haughton1James E. Lucas2Sophie G. Barlow3Timothy P. Fitzgerald4Alexander M. Litvintchouk5David Wu6Adelphi Real WorldAdelphi Real WorldAdelphi Real WorldAdelphi Real WorldJohnson & Johnson Innovative Medicine United StatesJohnson & Johnson Innovative Medicine United StatesJohnson & Johnson Innovative Medicine United StatesAbstract Introduction Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3–10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management. Methods Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses. Results Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores. Conclusion These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.https://doi.org/10.1007/s13555-025-01353-xPsoriasisCross-sectional studyDiagnosisTreatment patternsQuality of life |
| spellingShingle | Emily J. Goddard James M. Haughton James E. Lucas Sophie G. Barlow Timothy P. Fitzgerald Alexander M. Litvintchouk David Wu Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) Dermatology and Therapy Psoriasis Cross-sectional study Diagnosis Treatment patterns Quality of life |
| title | Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) |
| title_full | Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) |
| title_fullStr | Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) |
| title_full_unstemmed | Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) |
| title_short | Patient Disease Characteristics and Treatment Patterns in Mild–Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study) |
| title_sort | patient disease characteristics and treatment patterns in mild moderate psoriasis results from real world clinical practice in the united states prospect study |
| topic | Psoriasis Cross-sectional study Diagnosis Treatment patterns Quality of life |
| url | https://doi.org/10.1007/s13555-025-01353-x |
| work_keys_str_mv | AT emilyjgoddard patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT jamesmhaughton patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT jameselucas patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT sophiegbarlow patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT timothypfitzgerald patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT alexandermlitvintchouk patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy AT davidwu patientdiseasecharacteristicsandtreatmentpatternsinmildmoderatepsoriasisresultsfromrealworldclinicalpracticeintheunitedstatesprospectstudy |